If the Inflation Reduction Act (IRA) had been in effect when a novel autoimmune therapy was approved in 2007, the subsequent R&D for additional FDA approvals for other rare diseases might not have occurred.
As explored in this case study scenario, this would have resulted in significantly worse health outcomes, including more hospitalizations and blindness, for affected patients with the impacted autoimmune diseases (paroxysmal nocturnal haemoglobinuria [PNH], haemolytic uremic syndrome [HUS], myasthenia gravis [gMG], and neuromyelitis optica [NMO]).
The analysis was commissioned by the Partnership to Fight Chronic Disease (PFCD) and conducted by Lumanity.
